ProCE Banner Activity

Optimal Selection of Therapy for Treatment-Naive CLL

Slideset Download

Download this slideset from a live symposium at ASH 2022 for expert perspectives on best practices in frontline therapy for patients with CLL.

Released: December 09, 2022

Expiration: December 08, 2023

No longer available for credit.

Share

Faculty

Brian Hill

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Jennifer Woyach

Jennifer Woyach, MD

D Warren Brown Professor of Leukemia Research
Section Head, CLL and Hairy Cell Leukemia
Associate Division Director for Clinical Research
Division of Hematology
Co-Leader Leukemia Research Program
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

AstraZeneca

BeiGene

Lilly

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Faculty Disclosure

Primary Author

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Brian Hill, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Pharmacyclics.

Jennifer Woyach, MD

D Warren Brown Professor of Leukemia Research
Section Head, CLL and Hairy Cell Leukemia
Associate Division Director for Clinical Research
Division of Hematology
Co-Leader Leukemia Research Program
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Jennifer Woyach, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo, NewWave, Pharmacyclics; researcher: Schrödinger.